<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Mol Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Mol Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Mol. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Molecular Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5099</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28018172</article-id>
<article-id pub-id-type="pmc">5156834</article-id>
<article-id pub-id-type="doi">10.3389/fnmol.2016.00147</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Perspective</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>APP Causes Hyperexcitability in Fragile X Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Westmark</surname>
<given-names>Cara J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/83193/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chuang</surname>
<given-names>Shih-Chieh</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn002">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hays</surname>
<given-names>Seth A.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn002">
<sup>†</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/380709/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Filon</surname>
<given-names>Mikolaj J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ray</surname>
<given-names>Brian C.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Westmark</surname>
<given-names>Pamela R.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gibson</surname>
<given-names>Jay R.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/15043/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huber</surname>
<given-names>Kimberly M.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/5458/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wong</surname>
<given-names>Robert K. S.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Neurology, University of Wisconsin-Madison, Madison</institution>
<country>Madison, WI, USA</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Physiology and Pharmacology, State University of New York Downstate Medical Center</institution>
<country>Brooklyn, NY, USA</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Neuroscience, University of Texas Southwestern Medical Center</institution>
<country>Dallas, TX, USA</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Medicine, University of Wisconsin-Madison, Madison</institution>
<country>Madison, WI, USA</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Susan A. Masino, Trinity College, USA</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Barbara Bardoni, CNRS UMR7275 Institut de Pharmacologie Moléculaire et Cellulaire, France; Niraj S. Desai, University of Texas at Austin, USA</p>
</fn>
<corresp id="fn001">*Correspondence: Cara J. Westmark <email xlink:type="simple">westmark@facstaff.wisc.edu</email></corresp>
<fn fn-type="other" id="fn002">
<p>†These authors have contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>9</volume>
<elocation-id>147</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>9</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>12</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2016 Westmark, Chuang, Hays, Filon, Ray, Westmark, Gibson, Huber and Wong.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>Westmark, Chuang, Hays, Filon, Ray, Westmark, Gibson, Huber and Wong</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Amyloid-beta protein precursor (APP) and metabolite levels are altered in fragile X syndrome (FXS) patients and in the mouse model of the disorder, <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice. Normalization of APP levels in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice (<italic>Fmr1</italic><sup><italic>KO</italic></sup>/<italic>APP</italic><sup><italic>HET</italic></sup> mice) rescues many disease phenotypes. Thus, APP is a potential biomarker as well as therapeutic target for FXS. Hyperexcitability is a key phenotype of FXS. Herein, we determine the effects of APP levels on hyperexcitability in <italic>Fmr1</italic><sup><italic>KO</italic></sup> brain slices. <italic>Fmr1</italic><sup><italic>KO</italic></sup>/<italic>APP</italic><sup><italic>HET</italic></sup> slices exhibit complete rescue of UP states in a neocortical hyperexcitability model and reduced duration of ictal discharges in a CA3 hippocampal model. These data demonstrate that APP plays a pivotal role in maintaining an appropriate balance of excitation and inhibition (E/I) in neural circuits. A model is proposed whereby APP acts as a rheostat in a molecular circuit that modulates hyperexcitability through mGluR<sub>5</sub> and FMRP. Both over- and under-expression of APP in the context of the <italic>Fmr1</italic><sup><italic>KO</italic></sup> increases seizure propensity suggesting that an APP rheostat maintains appropriate E/I levels but is overloaded by mGluR<sub>5</sub>-mediated excitation in the absence of FMRP. These findings are discussed in relation to novel treatment approaches to restore APP homeostasis in FXS.</p>
</abstract>
<kwd-group>
<kwd>amyloid-beta</kwd>
<kwd>amyloid-beta precursor protein</kwd>
<kwd>fragile X mental retardation protein</kwd>
<kwd>fragile X syndrome</kwd>
<kwd>hyperexcitability</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">FRAXA Research Foundation<named-content content-type="fundref-id">10.13039/100000297</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn002">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source>
<award-id rid="cn002">R21AG044714</award-id>
<award-id rid="cn002">1R01HD056370</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="71"></ref-count>
<page-count count="8"></page-count>
<word-count count="6425"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Amyloid-beta protein precursor (APP) levels are dysregulated in numerous neurological disorders that are comorbid with a seizure phenotype including fragile X syndrome (FXS) (Westmark, <xref ref-type="bibr" rid="B57">2013</xref>). FXS is a trinucleotide repeat disorder caused by a CGG repeat expansion at the 5′-end of the <italic>FMR1</italic> gene. Hypermethylation of the repeat expansion results in transcriptional silencing of the <italic>FMR1</italic> gene and loss of expression of fragile X mental retardation protein (FMRP) (Jin and Warren, <xref ref-type="bibr" rid="B27">2000</xref>). FMRP is an RNA binding protein (RBP) that plays a pivotal role in synaptic function. It is one of numerous RBP that interact with <italic>amyloid precursor protein</italic> (<italic>App</italic>) mRNA to regulate post-transcriptional and/or translational events involved in the synthesis of APP (Westmark and Malter, <xref ref-type="bibr" rid="B60">2012</xref>). Specifically, FMRP binds to a guanine-rich region in the coding region of <italic>App</italic> mRNA and regulates APP translation through a metabotropic glutamate receptor 5 (mGluR<sub>5</sub>)-dependent pathway (Westmark and Malter, <xref ref-type="bibr" rid="B59">2007</xref>). We hypothesize that altered expression of APP in FXS contributes to disease severity. In support of this hypothesis, genetic knockout of one <italic>App</italic> allele in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice (<italic>Fmr1</italic><sup><italic>KO</italic></sup>/<italic>APP</italic><sup><italic>HET</italic></sup> mice) reduces APP expression in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> to wild type (WT) levels and rescues audiogenic-induced seizures (AGS), the percentage of mature spines, open field and marble burying behavioral phenotypes, and mGluR-LTD (Westmark et al., <xref ref-type="bibr" rid="B65">2011</xref>). APP and metabolite levels are altered in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice and FXS patients (Sokol et al., <xref ref-type="bibr" rid="B52">2006</xref>; Westmark et al., <xref ref-type="bibr" rid="B65">2011</xref>; Erickson et al., <xref ref-type="bibr" rid="B17">2014</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B45">2015</xref>; Ray et al., <xref ref-type="bibr" rid="B47">2016</xref>). Thus, APP is a potential therapeutic target as well as blood-based biomarker for FXS (Berry-Kravis et al., <xref ref-type="bibr" rid="B5">2013</xref>; Westmark et al., <xref ref-type="bibr" rid="B61">2016</xref>), and it is of interest to determine the effect(s) of APP levels on additional disease phenotypes. Herein, we ascertain the effects of <italic>App</italic> knockdown on hyperexcitability in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> mouse.</p>
</sec>
<sec id="s2">
<title>Genetic reduction of <italic>App</italic> rescues hyperexcitability in <italic>Fmr1<sup><italic>KO</italic></sup></italic> mice</title>
<p>The psychiatric phenotype of FXS includes hyperexcitability traits such as tactile defensiveness, attention deficits, hyperactivity, and hyperarousal to sensory stimulation (Tranfaglia, <xref ref-type="bibr" rid="B55">2011</xref>). There is high comorbidity of epilepsy in FXS with electroencephalogram (EEG) patterns most often consisting of a centrotemporal spike pattern resembling Benign Focal Epilepsy of Childhood (BFEC) (Berry-Kravis, <xref ref-type="bibr" rid="B4">2002</xref>). Hyperexcitability can be modeled in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice both <italic>in vivo</italic> and <italic>in vitro</italic> (brain slices). <italic>In vivo</italic>, the <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice are susceptible to AGS (Chen and Toth, <xref ref-type="bibr" rid="B13">2001</xref>). In the AGS model, mice are exposed to 110 dB siren, which elicits out-of-control (wild) running and jumping followed by convulsive seizures and often death. There is substantial evidence that dysregulated APP expression alters seizure propensity. AGS are exacerbated by overexpression of APP in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> mouse (FRAXAD mice) and partially rescued by reduced expression of APP in <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/APP</italic><sup><italic>HET</italic></sup> mice (Westmark et al., <xref ref-type="bibr" rid="B63">2010</xref>, <xref ref-type="bibr" rid="B65">2011</xref>). Alzheimer's disease (Tg2576) and Down syndrome (Ts65Dn) mice, which overexpress human and mouse APP respectively, are highly susceptible to AGS (Westmark et al., <xref ref-type="bibr" rid="B63">2010</xref>). Numerous mouse models that express altered APP or metabolite levels exhibit elevated rates of spontaneous or provoked seizures (Moechars et al., <xref ref-type="bibr" rid="B38">1996</xref>; Steinbach et al., <xref ref-type="bibr" rid="B53">1998</xref>; Del Vecchio et al., <xref ref-type="bibr" rid="B15">2004</xref>; Lalonde et al., <xref ref-type="bibr" rid="B30">2005</xref>; Palop et al., <xref ref-type="bibr" rid="B43">2007</xref>; Kobayashi et al., <xref ref-type="bibr" rid="B29">2008</xref>; Westmark et al., <xref ref-type="bibr" rid="B62">2008</xref>; Minkeviciene et al., <xref ref-type="bibr" rid="B37">2009</xref>; Ziyatdinova et al., <xref ref-type="bibr" rid="B71">2011</xref>; Sanchez et al., <xref ref-type="bibr" rid="B51">2012</xref>) while suppression of transgenic APP in Alzheimer's disease mice during postnatal development delays the onset of EEG abnormalities (Born et al., <xref ref-type="bibr" rid="B7">2014</xref>).</p>
<p>In brain slices, hyperexcitability can be measured by recording UP states and epileptiform discharges. UP states are short periods of local network activity that generate a steady-state level of depolarization and synchronous firing among groups of neighboring neurons (Gibson et al., <xref ref-type="bibr" rid="B20">2008</xref>). <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice exhibit an increased duration of the UP state, consistent with network hyperexcitability (Gibson et al., <xref ref-type="bibr" rid="B20">2008</xref>; Goncalves et al., <xref ref-type="bibr" rid="B21">2013</xref>). Specifically, spontaneously occurring UP states are 38-67% longer in <italic>Fmr1</italic><sup><italic>KO</italic></sup> than in WT slices (Hays et al., <xref ref-type="bibr" rid="B23">2011</xref>). Deletion of <italic>Fmr1</italic> selectively in excitatory neurons mimics the prolonged UP states whereas knockdown of mGluR<sub>5</sub> rescues the hyperexcitability in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> with no effect in WT (Hays et al., <xref ref-type="bibr" rid="B23">2011</xref>). To determine if hyperexcitability was rescued in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice by knockdown of <italic>App</italic>, we recorded UP states in <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> mice and littermate controls per previously described methods (Gibson et al., <xref ref-type="bibr" rid="B20">2008</xref>). Briefly, <italic>Fmr1</italic><sup><italic>HET</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> females were bred with <italic>App</italic><sup><italic>HET</italic></sup> males to generate WT, <italic>Fmr1</italic><sup><italic>KO</italic></sup>, <italic>App</italic><sup><italic>HET</italic></sup> and <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> male littermates. Thalamocortical slices (400 μm) from postnatal day 24–28 (P24-P28) males were transected parallel to the pia mater to remove the thalamus and midbrain, and spontaneously generated UP states were recorded in layer 4 of the somatosensory cortex. The increased duration of the UP states observed in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> was completely rescued in <italic>Fmr1</italic><sup><italic>KO</italic></sup>/<italic>APP</italic><sup><italic>HET</italic></sup> mice (Figures <xref ref-type="fig" rid="F1">1A,B</xref>) where UP state duration decreased from 931 ± 55 milliseconds (ms) in <italic>Fmr1</italic><sup><italic>KO</italic></sup> to 597 ± 30 ms in <italic>Fmr1</italic><sup><italic>KO</italic></sup>/<italic>APP</italic><sup><italic>HET</italic></sup>, (<italic>p</italic> &lt; 0.001). UP state duration was not significantly different between <italic>APP</italic><sup><italic>HET</italic></sup> and WT slices suggesting that rescue was not a consequence of a general reduction in excitability due to lower APP levels.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>Rescue of hyperexcitability in <italic><bold>Fmr1</bold></italic><sup><italic><bold>KO</bold></italic></sup> mice by genetic manipulation of <italic><bold>APP</bold></italic></bold>. Thalamocortical slices from WT (<italic>n</italic> = 17), <italic>Fmr1</italic><sup><italic>KO</italic></sup> (<italic>n</italic> = 22), <italic>App</italic><sup><italic>HET</italic></sup> (<italic>n</italic> = 13), and <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> (<italic>n</italic> = 13) male mice were assessed for neocortical hyperexcitability. <bold>(A)</bold> Trace recordings and <bold>(B)</bold> histogram depicting a significant increase in UP state activity in <italic>Fmr1</italic><sup><italic>KO</italic></sup> slices compared to WT, which was completely rescued in the <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup>. Error bars represent SEM. Horizontal bars denote statistically different levels by one-way ANOVA and Bonferroni's multiple comparison test (<italic>P</italic> &lt; 0.0001). DHPG-induced prolonged epileptiform discharges were assessed in hippocampal slices from <italic>Fmr1</italic><sup><italic>KO</italic></sup> and <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> male mice (<italic>n</italic> = 6 mice per cohort). The recordings were continuous for 3 or more hours in a single slice per animal. <bold>(C)</bold> Summary frequency histogram of synchronized epileptiform discharges from <italic>Fmr1</italic><sup><italic>KO</italic></sup> and <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> slices in the presence of DHPG (60 min) and after DHPG washout at the indicated times up to 2 h. The mean durations of epileptiform discharges in <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> slices at 30, 60, 90, and 120 min after DHPG washout are significantly shorter than those in <italic>Fmr1</italic><sup><italic>KO</italic></sup> for all times tested (<italic>P</italic> &lt; 0.001).</p>
</caption>
<graphic xlink:href="fnmol-09-00147-g0001"></graphic>
</fig>
<p>Hyperexcitability can also be evaluated in slices of the CA3 region of the hippocampus in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice. Prolonged epileptic bursts can be induced by group 1 mGluR agonists in both WT and <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice and with a GABAergic antagonist only in <italic>Fmr1</italic><sup><italic>KO</italic></sup> (Chuang et al., <xref ref-type="bibr" rid="B14">2005</xref>; Zhong et al., <xref ref-type="bibr" rid="B70">2009</xref>). In WT slices, DHPG elicits short (~500 ms) synchronized discharges that gradually extend to reach an average duration of 4.4 ± 0.14 s at 60 min; and in untreated <italic>Fmr1</italic><sup><italic>KO</italic></sup> slices, bicuculline elicits short &lt;1 ms synchronized discharges that progressively increase in duration over 60 min (average duration 2.3 ïĆś 0.13 s) (Osterweil et al., <xref ref-type="bibr" rid="B41">2013</xref>). These prolonged epileptiform discharges resemble the ictal discharges observed in the CA3 region in epilepsy (Merlin and Wong, <xref ref-type="bibr" rid="B34">1997</xref>; Wong et al., <xref ref-type="bibr" rid="B66">2004</xref>). The number and duration of ictal-like discharges were assessed by intracellular CA3 recordings in juvenile <italic>Fmr1</italic><sup><italic>KO</italic></sup> and <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> slices in the presence of DHPG (60 min) and after DHPG washout for up to 2 h as previously described (Chuang et al., <xref ref-type="bibr" rid="B14">2005</xref>) (Figure <xref ref-type="fig" rid="F1">1C</xref>, Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">1</xref>). In the presence of DHPG, a distinct population of ictal-like discharges (burst duration &gt; 1500 ms) occurred in both <italic>Fmr1</italic><sup><italic>KO</italic></sup> and <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> slices. After DHPG washout, the ictal-like discharges remained distinct for the duration of the recording (up to 2 h post-DHPG washout) in the <italic>Fmr1</italic><sup><italic>KO</italic></sup>, but not in the <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> slices. Thus, a major difference between <italic>Fmr1</italic><sup><italic>KO</italic></sup> and <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> slices is that while ictal-like discharges were transiently expressed in both genotypes, they were not maintained in the <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> upon termination of receptor stimulation. The seizure activity modeled in the hippocampal slice paradigm is congruent with the AGS phenotype observed in <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> mice where wild running and seizures are attenuated but not completely rescued to WT levels (Westmark et al., <xref ref-type="bibr" rid="B65">2011</xref>). The two critical components of plasticity include the initiating factors required for induction of the modification and the downstream effectors that maintain expression of the enhanced response (Bianchi et al., <xref ref-type="bibr" rid="B6">2012</xref>). Our data suggest that genetic reduction of <italic>App</italic> in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> background does not prevent the induction of seizure activity, but can attenuate progression; thus, APP appears to be a downstream effector that maintains hyperexcitability in the context of the <italic>Fmr1</italic><sup><italic>KO</italic></sup>.</p>
<p>The complete rescue of hyperexcitability in the neocortex compared to the partial rescue in the hippocampus in the <italic>Fmr1</italic><sup><italic>KO</italic></sup>/<italic>App</italic><sup><italic>HET</italic></sup> mice is in accord with studies in immature mice demonstrating that the hippocampus has a lower seizure threshold compared to neocortex (Abdelmalik et al., <xref ref-type="bibr" rid="B1">2005</xref>). This could be due differential expression and/or activity of group 1 mGluRs (mGluR<sub>1</sub> and mGluR<sub>5</sub>) in the respective neurons under study. In fast spiking inhibitory neurons (neocortical slice model), mGluR<sub>1</sub> is more highly expressed than mGluR<sub>5</sub> (Sun et al., <xref ref-type="bibr" rid="B54">2009</xref>); however reduced expression of mGluR<sub>5</sub> or APP in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> completely rescues neocortical hyperexcitability whereas UP states are still longer in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> after treatment with the mGluR<sub>1</sub> inhibitor LY367385 (Hays et al., <xref ref-type="bibr" rid="B23">2011</xref>). These data suggest that mGluR<sub>5</sub> is the critical group 1 mGluR that modulates <italic>Fmr1</italic>-dependent hyperexcitability in the neocortex. Alternatively, in CA3 hippocampal neurons, both group 1 mGluR subtypes are involved in the induction and maintenance of mGluR-mediated bursts, but mGluR<sub>5</sub> plays a greater role in the induction and mGluR<sub>1</sub> in the maintenance of the prolonged epileptic bursts (Merlin, <xref ref-type="bibr" rid="B33">2002</xref>). As burst duration but not induction are rescued in the <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/APP</italic><sup><italic>HET</italic></sup>, these data suggest that the hyperexcitability elicited by elevated APP expression in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> CA3 region is dependent on mGluR<sub>1</sub>.</p>
<p>Synaptic dysfunction occurs when the appropriate balance of excitation and inhibition (E/I) in neural circuits is not maintained (Gatto and Broadie, <xref ref-type="bibr" rid="B19">2010</xref>). The absence of FMRP during postnatal development results in an E/I imbalance dominated by excitation. Our results demonstrate that E/I balance is predominantly restored when APP expression is reduced to WT levels in the <italic>Fmr1</italic><sup><italic>KO</italic></sup>. Thus, APP plays a critical role in modulating excitability. The other half of E/I balance is the inhibitory feedback on circuits. FMRP normally binds to multiple GABA<sub><italic>A</italic></sub>R mRNAs, and their expression is decreased in juvenile <italic>Fmr1</italic><sup><italic>KO</italic></sup> (Braat et al., <xref ref-type="bibr" rid="B8">2015</xref>) resulting in delay of the developmental GABA switch in <italic>Fmr1</italic><sup><italic>KO</italic></sup> (He et al., <xref ref-type="bibr" rid="B24">2014</xref>). Selective deletion of <italic>Fmr1</italic> in inhibitory neurons has no effect on prolonged UP states suggesting that impaired GABA<sub><italic>A</italic></sub>R signaling in FXS does not account for increased hyperexcitability in the neocortex (Hays et al., <xref ref-type="bibr" rid="B23">2011</xref>). Conversely, a competitive antagonist of GABA<sub><italic>A</italic></sub>R, bicuculline, elicits epileptiform discharges in the CA3 region of the hippocampus (Osterweil et al., <xref ref-type="bibr" rid="B41">2013</xref>). These findings suggest that inhibitory feedback is differentially regulated in the neocortex and hippocampus in <italic>Fmr1</italic><sup><italic>KO</italic></sup>. Overall, the neocortical hyperexcitability and hippocampal epileptiform discharge slice models share the features of prolonged activity states and dependence on mGluR<sub>5</sub>, FMRP, and APP, but differ in induction mode (neocortical slices exhibit baseline excitation vs. hippocampal slices require pharmacological stimulation), inhibitory feedback (hippocampal slices are dependent of GABA<sub><italic>A</italic></sub>R), and protein synthesis requirements (CA3 bursts require extracellular signal-regulated kinase (ERK)1/2 activation and new protein synthesis) (Zhao et al., <xref ref-type="bibr" rid="B68">2004</xref>; Chuang et al., <xref ref-type="bibr" rid="B14">2005</xref>; Hays et al., <xref ref-type="bibr" rid="B23">2011</xref>).</p>
</sec>
<sec id="s3">
<title>A model for an APP-induced short circuit in fragile X</title>
<p>Regarding possible mechanisms for APP-mediated hyperexcitability, (Westmark, <xref ref-type="bibr" rid="B57">2013</xref>) APP or a metabolite could interfere with cell surface receptor activation. For example, Aβ oligomers cause redistribution of mGluR<sub>5</sub>to synapses (Renner et al., <xref ref-type="bibr" rid="B48">2010</xref>) and trigger multiple distinct signaling events through mGluR<sub>5</sub>/prion protein complexes (Um et al., <xref ref-type="bibr" rid="B56">2013</xref>; Hu et al., <xref ref-type="bibr" rid="B26">2014</xref>; Haas and Strittmatter, <xref ref-type="bibr" rid="B22">2016</xref>). In neurons that overexpress APP, Aβ depresses excitatory synaptic transmission (Kamenetz et al., <xref ref-type="bibr" rid="B28">2003</xref>). In <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice, Aβ levels are elevated in older mice but reduced in juvenile mice compared to WT controls (Westmark et al., <xref ref-type="bibr" rid="B65">2011</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B45">2015</xref>). Thus, increased α-secretase and/or decreased BACE1 processing during postnatal development could result in decreased Aβ levels and increased synaptic transmission (Jin and Warren, <xref ref-type="bibr" rid="B27">2000</xref>) Altered APP expression could affect scaffolding protein interactions at the postsynaptic density. For example, APP co-immunoprecipitates with Homer2 and Homer3 (Parisiadou et al., <xref ref-type="bibr" rid="B44">2008</xref>). These scaffolding proteins inhibit APP processing, reduce cell surface APP expression, and prevent maturation of BACE1 (Parisiadou et al., <xref ref-type="bibr" rid="B44">2008</xref>). Uncoupled Homer1-mGluR<sub>5</sub> interactions underlie <italic>Fmr1</italic><sup><italic>KO</italic></sup> phenotypes, and genetic deletion of Homer1a rescues prolonged UP states in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice similar to the complete rescue observed herein in the <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/APP</italic><sup><italic>HET</italic></sup> mice (Ronesi et al., <xref ref-type="bibr" rid="B49">2012</xref>). APP does not co-immunoprecipitate with Homer1 (Parisiadou et al., <xref ref-type="bibr" rid="B44">2008</xref>); however, Aβ induces disassembly of Homer1b and Shank1 clusters (Roselli et al., <xref ref-type="bibr" rid="B50">2009</xref>). (Westmark and Malter, <xref ref-type="bibr" rid="B60">2012</xref>) APP or metabolites could alter the activity of intracellular signaling pathways such as ERK and mTOR (Young et al., <xref ref-type="bibr" rid="B67">2009</xref>; Ma et al., <xref ref-type="bibr" rid="B32">2010</xref>; Caccamo et al., <xref ref-type="bibr" rid="B9">2011</xref>; Chasseigneaux et al., <xref ref-type="bibr" rid="B12">2011</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B45">2015</xref>). Both of these pathways play pivotal roles in FXS pathology (Osterweil et al., <xref ref-type="bibr" rid="B42">2010</xref>; Hoeffer et al., <xref ref-type="bibr" rid="B25">2012</xref>). And Westmark and Malter (<xref ref-type="bibr" rid="B59">2007</xref>) APP metabolites could function in feedback loops to regulate the aforementioned pathways or even the transcription of the APP and APP processing enzymes. Aβ binds to the promoter regions of the APP and BACE1 genes and may function as a transcription factor to regulate its own production and/or processing (Bailey et al., <xref ref-type="bibr" rid="B3">2011</xref>). Thus, there are numerous molecular junctures where altered expression of APP or metabolites could interfere with synaptic function and lead to a hyperexcitable circuit.</p>
<p>Overall, these data suggest a model whereby mGluR<sub>5</sub> inhibitors act as a circuit breaker, FMRP as an automatic transfer switch and APP as a rheostat in a circuit that controls hyperexcitability (Figure <xref ref-type="fig" rid="F2">2</xref>). <italic>The mGluR</italic><sub>5</sub>
<italic>circuit breaker</italic>: Genetic reduction of mGluR<sub>5</sub> in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> mouse rescues plasticity (ocular dominance plasticity, neocortical hyperexcitability), dendritic spines (density on cortical pyramidal neurons), protein synthesis, behavior (inhibitory avoidance extinction), and AGS (Dolen et al., <xref ref-type="bibr" rid="B16">2007</xref>; Hays et al., <xref ref-type="bibr" rid="B23">2011</xref>). Pharmaceutical inhibition of mGluR<sub>5</sub> likewise rescues numerous <italic>Fmr1</italic><sup><italic>KO</italic></sup> phenotypes (Michalon et al., <xref ref-type="bibr" rid="B36">2012</xref>, <xref ref-type="bibr" rid="B35">2014</xref>). Thus, inhibiting mGluR<sub>5</sub> appears to break a circuit that mediates hyperexcitability in the <italic>Fmr1</italic><sup><italic>KO</italic></sup> mouse. <italic>The FMRP automatic transfer switch</italic>: mGluR<sub>5</sub> activation causes a rapid dephosphorylation of FMRP, which permits protein synthesis (Ceman et al., <xref ref-type="bibr" rid="B11">2003</xref>; Narayanan et al., <xref ref-type="bibr" rid="B40">2007</xref>), as well as a biphasic change in FMRP levels (initial decrease followed by increase) (Zhao et al., <xref ref-type="bibr" rid="B69">2011</xref>). Thus, FMRP appears to function as an automatic transfer switch downstream of mGluR<sub>5</sub> to control protein synthesis in response to receptor activation. In FXS models, loss of the FMRP switch that modulates mGluR<sub>5</sub> signaling permits a constitutively-on circuit. <italic>The APP rheostat</italic>: Born and colleagues demonstrated that juvenile overexpression of APP contributes to sharp wave EEG discharges in APP transgenic mice, and proposed that APP expression functions as a rheostat that regulates synaptic balance in the brain (Born et al., <xref ref-type="bibr" rid="B7">2014</xref>). We have observed that both over- and under-expression of APP increases seizure propensity in juvenile <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice suggesting that tight regulation of this protein may be necessary to mitigate hyperexcitability in FXS (Westmark et al., <xref ref-type="bibr" rid="B63">2010</xref>, <xref ref-type="bibr" rid="B65">2011</xref>). Genetic reduction of APP in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice rescues plasticity (mGluR-LTD, neocortical hyperexcitability, epileptiform discharge duration but not induction), dendritic spines (percent mature spines but not dendritic spine length), protein synthesis, behavior (open field, marble burying), and AGS (Westmark et al., <xref ref-type="bibr" rid="B65">2011</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B45">2015</xref>). The partial rescue of dendritic spines and epileptiform discharges in the <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/APP</italic><sup><italic>HET</italic></sup> suggests that APP is necessary but not sufficient to maintain synaptic homeostasis. Thus, in the context of WT mice, an APP variable resistor is capable of maintaining an appropriate E/I balance, but in <italic>Fmr1</italic><sup><italic>KO</italic></sup> and some APP transgenic mice, excess APP appears to cause a short circuit through overload of the APP rheostat resulting in hyperexcitability. Likewise, complete loss of APP would bypass the APP rheostat. <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>KO</italic></sup> mice exhibit an extremely strong AGS phenotype (97%, <italic>n</italic> = 36 mice) (Westmark et al., <xref ref-type="bibr" rid="B64">2013a</xref>), which is not observed in <italic>App</italic><sup><italic>KO</italic></sup> mice (11%, <italic>n</italic> = 36 mice). These data suggest that exacerbated hyperexcitability is a result of the combined loss of both FMRP and APP.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p><bold>Model for an APP-induced short circuit in FXS</bold>. APP acts as a rheostat (i.e., variable resistor, dimmer switch) in a circuit where mGluR<sub>5</sub> inhibitors are a circuit breaker and FMRP is an automatic transfer switch that regulate neuronal excitability. The FMRP switch is dependent on a rapid dephosphorylation reaction in response to mGluR<sub>5</sub> activation. In the absence of FMRP, the circuit is constitutively on. In the presence of mGluR<sub>5</sub> inhibitors, the circuit is shut down. The downstream APP circuitry appears to be wired differently dependent on brain region. In the neocortex, knockdown of individual proteins including mGluR<sub>5</sub>, Homer and APP completely rescues excitability levels suggesting that these components are arranged in a parallel circuit whereby there is more than one continuous signaling pathway between mGluR<sub>5</sub> activation and excitability output. Rescue of any one of the parallel components is sufficient to restore synaptic homeostasis. In the hippocampus, ictal burst duration, but not induction, is rescued in <italic>Fmr1</italic><sup><italic>KO</italic></sup><italic>/App</italic><sup><italic>HET</italic></sup> slices in response to DHPG treatment. This incomplete rescue suggests that APP and FMRP are wired in series downstream of mGluR<sub>5</sub>, and that the APP rheostat is overloaded in the absence of FMRP resulting in a short circuit. This model has important implications for therapeutic development and suggests that APP should be considered as a drug target for FXS as part of a multi-drug therapeutic strategy.</p>
</caption>
<graphic xlink:href="fnmol-09-00147-g0002"></graphic>
</fig>
<p>APP and metabolites play key roles in regulating synaptic activity with both Aβ and sAPPα implicated in positive feedback loops that facilitate mGluR<sub>5</sub> signaling (Casley et al., <xref ref-type="bibr" rid="B10">2009</xref>; Renner et al., <xref ref-type="bibr" rid="B48">2010</xref>; Ferreira and Klein, <xref ref-type="bibr" rid="B18">2011</xref>; Westmark et al., <xref ref-type="bibr" rid="B65">2011</xref>, <xref ref-type="bibr" rid="B58">2013b</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B45">2015</xref>). Thus, the APP rheostat may provide a graded response to mGluR<sub>5</sub> activation through feedback loops involving amyloidogenic and non-amyloidogenic secretase processing. We found that AGS are attenuated in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice with BACE1 inhibitor treatment (Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">2</xref>). Prox and colleagues found that seizures are increased in the ADAM10 conditional knockout mouse (loss of α-secretase processing) (Prox et al., <xref ref-type="bibr" rid="B46">2013</xref>). The effect of sAPPα overexpression on hyperexcitability, which could be studied in TgAPPα (Bailey et al., <xref ref-type="bibr" rid="B2">2013</xref>) and TgAPPα/<italic>Fmr1</italic><sup><italic>KO</italic></sup> mice, remains to be determined. Thus, multiple APP fragments may play roles in hyperexcitability and seizure susceptibility. A caveat to this model is that over-expression of APP alone is not sufficient to increase seizure propensity in either WT or <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice. We tested seizures in two alternative Alzheimer's disease mouse models, R1.40 and J20, which exhibit elevated APP expression (Lamb et al., <xref ref-type="bibr" rid="B31">1997</xref>; Mucke et al., <xref ref-type="bibr" rid="B39">2000</xref>). Neither strain exhibited a strong AGS phenotype (Supplementary Figures <xref ref-type="supplementary-material" rid="SM1">3</xref>, <xref ref-type="supplementary-material" rid="SM1">4</xref>) in contrast to Tg2576 and Ts65Dn (Westmark et al., <xref ref-type="bibr" rid="B63">2010</xref>). A genetic cross of J20 with <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice that produced mice over-expressing human APP in the context of the <italic>Fmr1</italic><sup><italic>KO</italic></sup> background did not result in exacerbated AGS rates in comparison to <italic>Fmr1</italic><sup><italic>KO</italic></sup> unlike the FRAXAD mice (cross of Tg2576 with <italic>Fmr1</italic><sup><italic>KO</italic></sup>) (Westmark et al., <xref ref-type="bibr" rid="B63">2010</xref>). The inclusion of flanking sequences in the transgenic constructs used for the R1.40 and J20 mice are expected to affect posttranscriptional regulation of the <italic>APP</italic> gene, which could alter the temporal and spatial expression of APP and metabolites and thus their contribution to seizure threshold. Of note, <italic>Fmr1</italic><sup><italic>HET</italic></sup>/J20 female mice exhibited a 50% wild running rate, which was significantly higher than WT, <italic>Fmr1</italic><sup><italic>HET</italic></sup> and J20 controls, supporting the assertion that APP works in synergy with FMRP to regulate hyperexcitability (Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">4</xref>). This synergistic effect is also observed in mGluR-LTD studies where loss of FMRP and APP modulate synaptic transmission in opposite directions (Westmark et al., <xref ref-type="bibr" rid="B65">2011</xref>). The <italic>Fmr1</italic><sup><italic>KO</italic></sup>/<italic>APP</italic><sup><italic>HET</italic></sup> mice used herein were a constitutive <italic>App</italic> knockdown. It remains to be determined how conditional knockdown of <italic>App</italic> during development affects <italic>Fmr1</italic> phenotypes.</p>
</sec>
<sec id="s4">
<title>Relevance to therapeutic development</title>
<p>All major <italic>Fmr1</italic><sup><italic>KO</italic></sup> phenotypes can be corrected by inhibition or knockdown of mGluR<sub>5</sub> in mice; however, neural circuitry is likely more complicated in humans and it may be necessary to employ pharmaceutical cocktails for disease treatment. Drugs under study for FXS such as acamprosate, AFQ056, donepezil, ganaxolone, lithium, lovastatin, memantine, minocycline and sertraline exhibit on- and/or off-site effects that are expected to modulate APP, Aβ, BACE1, and/or ADAM10 (Westmark et al., <xref ref-type="bibr" rid="B58">2013b</xref>). Targeting APP and metabolites in FXS may allow fine tuning of excitability levels as part of a multi-drug therapeutic approach. Both amyloidogenic and non-amyloidogenic therapies have been proposed to treat FXS (Westmark et al., <xref ref-type="bibr" rid="B58">2013b</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B45">2015</xref>). Both amyloidogenic (Aβ<sub>1−42</sub>) and non-amyloidogenic (sAPPα) metabolites of APP stimulate phosphorylation of ERK and modulate synthesis of multiple synaptic proteins predicted to be regulated through mGluR<sub>5</sub>/FMRP and to contribute to altered synaptic plasticity (Westmark et al., <xref ref-type="bibr" rid="B65">2011</xref>; Pasciuto et al., <xref ref-type="bibr" rid="B45">2015</xref>). Thus, it may be necessary to simultaneously modulate both α- and β-secretase processing to attain homeostatic levels of APP metabolites and rescue hyperexcitability in FXS.</p>
</sec>
<sec id="s5">
<title>Author contributions</title>
<p>CW, JG, KH, RW conceived and designed the experiments. CW, SC, SH, MF, BR, PW acquired data. CW, SC, SH, JG, KH, RW interpreted data. CW drafted the manuscript.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>This work was funded by FRAXA Research Foundation and NIH R21AG044714 (CW), and NIH 1R01HD056370 (JG).</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>The authors thank the Research Animal Resources Centers (RARC) staffs at the University of Wisconsin, the State University of New York Downstate Medical Center and the University of Texas Southwestern for expert animal care and assistance with transport between facilities. All mouse procedures were performed in accordance with NIH guidelines and approved University of Wisconsin-Madison, State University of New York Downstate Medical Center and University of Texas Southwestern Medical Center animal care protocols administered through their RARC.</p>
</ack>
<sec id="s7" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="http://journal.frontiersin.org/article/10.3389/fnmol.2016.00147/full#supplementary-material">http://journal.frontiersin.org/article/10.3389/fnmol.2016.00147/full#supplementary-material</ext-link></p>
<supplementary-material content-type="local-data" id="SM1">
<media xlink:href="Image1.PDF">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelmalik</surname><given-names>P. A.</given-names></name><name><surname>Burnham</surname><given-names>W. M.</given-names></name><name><surname>Carlen</surname><given-names>P. L.</given-names></name></person-group> (<year>2005</year>). <article-title>Increased seizure susceptibility of the hippocampus compared with the neocortex of the immature mouse brain <italic>in vitro</italic></article-title>. <source/>Epilepsia
<volume>46</volume>, <fpage>356</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1111/j.0013-9580.2005.34204.x</pub-id><pub-id pub-id-type="pmid">15730532</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>A. R.</given-names></name><name><surname>Hou</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>M.</given-names></name><name><surname>Obregon</surname><given-names>D. F.</given-names></name><name><surname>Portis</surname><given-names>S.</given-names></name><name><surname>Barger</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>GFAP expression and social deficits in transgenic mice overexpressing human sAPPalpha</article-title>. <source/>Glia
<volume>61</volume>, <fpage>1556</fpage>–<lpage>1569</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22544</pub-id><pub-id pub-id-type="pmid">23840007</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>J. A.</given-names></name><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Ge</surname><given-names>Y. W.</given-names></name><name><surname>Lahiri</surname><given-names>D. K.</given-names></name></person-group> (<year>2011</year>). <article-title>Functional activity of the novel Alzheimer's amyloid beta-peptide interacting domain (AbetaID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis</article-title>. <source/>Gene
<volume>488</volume>, <fpage>13</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2011.06.017</pub-id><pub-id pub-id-type="pmid">21708232</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry-Kravis</surname><given-names>E.</given-names></name></person-group> (<year>2002</year>). <article-title>Epilepsy in fragile X syndrome</article-title>. <source/>Dev. Med. Child Neurol.
<volume>44</volume>, <fpage>724</fpage>–<lpage>728</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.2002.tb00277.x</pub-id><pub-id pub-id-type="pmid">12418611</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry-Kravis</surname><given-names>E.</given-names></name><name><surname>Hessl</surname><given-names>D.</given-names></name><name><surname>Abbeduto</surname><given-names>L.</given-names></name><name><surname>Reiss</surname><given-names>A. L.</given-names></name><name><surname>Beckel-Mitchener</surname><given-names>A.</given-names></name><name><surname>Urv</surname><given-names>T. K.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Outcome measures for clinical trials in fragile x syndrome</article-title>. <source/>J. Dev. Behav. Pediatr.
<volume>34</volume>, <fpage>508</fpage>–<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1097/DBP.0b013e31829d1f20</pub-id><pub-id pub-id-type="pmid">24042082</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>R.</given-names></name><name><surname>Wong</surname><given-names>R. K. S.</given-names></name><name><surname>Merlin</surname><given-names>L. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Glutamate receptors in epilepsy: group I mGluR-mediated epileptogenesis</article-title>, in <source/>Jasper's Basic Mechanisms of the Epilepsies, 4th Edn., eds <person-group person-group-type="editor"><name><surname>Noebels</surname><given-names>J. L.</given-names></name><name><surname>Avoli</surname><given-names>M.</given-names></name><name><surname>Rogawski</surname><given-names>M. A.</given-names></name><name><surname>Olsen</surname><given-names>R. W.</given-names></name><name><surname>Delgado-Escueta</surname><given-names>A. V.</given-names></name></person-group> (<publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>). <pub-id pub-id-type="doi">10.1093/med/9780199746545.003.0011</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Born</surname><given-names>H. A.</given-names></name><name><surname>Kim</surname><given-names>J. Y.</given-names></name><name><surname>Savjani</surname><given-names>R. R.</given-names></name><name><surname>Das</surname><given-names>P.</given-names></name><name><surname>Dabaghian</surname><given-names>Y. A.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzheimer's disease</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>3826</fpage>–<lpage>3840</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5171-13.2014</pub-id><pub-id pub-id-type="pmid">24623762</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braat</surname><given-names>S.</given-names></name><name><surname>D'Hulst</surname><given-names>C.</given-names></name><name><surname>Heulens</surname><given-names>I.</given-names></name><name><surname>De Rubeis</surname><given-names>S.</given-names></name><name><surname>Mientjes</surname><given-names>E.</given-names></name><name><surname>Nelson</surname><given-names>D. L.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome</article-title>. <source/>Cell Cycle
<volume>14</volume>, <fpage>2985</fpage>–<lpage>2995</lpage>. <pub-id pub-id-type="doi">10.4161/15384101.2014.989114</pub-id><pub-id pub-id-type="pmid">25790165</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caccamo</surname><given-names>A.</given-names></name><name><surname>Maldonado</surname><given-names>M. A.</given-names></name><name><surname>Majumder</surname><given-names>S.</given-names></name><name><surname>Medina</surname><given-names>D. X.</given-names></name><name><surname>Holbein</surname><given-names>W.</given-names></name><name><surname>Magri</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism</article-title>. <source/>J. Biol. Chem.
<volume>286</volume>, <fpage>8924</fpage>–<lpage>8932</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.180638</pub-id><pub-id pub-id-type="pmid">21266573</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casley</surname><given-names>C. S.</given-names></name><name><surname>Lakics</surname><given-names>V.</given-names></name><name><surname>Lee</surname><given-names>H. G.</given-names></name><name><surname>Broad</surname><given-names>L. M.</given-names></name><name><surname>Day</surname><given-names>T. A.</given-names></name><name><surname>Cluett</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide</article-title>. <source/>Brain Res. <volume>1260</volume>, <fpage>65</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2008.12.082</pub-id><pub-id pub-id-type="pmid">19401173</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceman</surname><given-names>S.</given-names></name><name><surname>O'Donnell</surname><given-names>W. T.</given-names></name><name><surname>Reed</surname><given-names>M.</given-names></name><name><surname>Patton</surname><given-names>S.</given-names></name><name><surname>Pohl</surname><given-names>J.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name></person-group> (<year>2003</year>). <article-title>Phosphorylation influences the translation state of FMRP-associated polyribosomes</article-title>. <source/>Hum. Mol. Genet.
<volume>12</volume>, <fpage>3295</fpage>–<lpage>3305</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddg350</pub-id><pub-id pub-id-type="pmid">14570712</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chasseigneaux</surname><given-names>S.</given-names></name><name><surname>Dinc</surname><given-names>L.</given-names></name><name><surname>Rose</surname><given-names>C.</given-names></name><name><surname>Chabret</surname><given-names>C.</given-names></name><name><surname>Coulpier</surname><given-names>F.</given-names></name><name><surname>Topilko</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Secreted amyloid precursor protein beta and secreted amyloid precursor protein alpha induce axon outgrowth <italic>in vitro</italic> through Egr1 signaling pathway</article-title>. <source/>PLoS ONE
<volume>6</volume>:<fpage>e16301</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0016301</pub-id><pub-id pub-id-type="pmid">21298006</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Toth</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Fragile X mice develop sensory hyperreactivity to auditory stimuli</article-title>. <source/>Neuroscience
<volume>103</volume>, <fpage>1043</fpage>–<lpage>1050</lpage>. <pub-id pub-id-type="doi">10.1016/S0306-4522(01)00036-7</pub-id><pub-id pub-id-type="pmid">11301211</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>S. C.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Bauchwitz</surname><given-names>R.</given-names></name><name><surname>Yan</surname><given-names>Q.</given-names></name><name><surname>Bianchi</surname><given-names>R.</given-names></name><name><surname>Wong</surname><given-names>R. K.</given-names></name></person-group> (<year>2005</year>). <article-title>Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model</article-title>. <source/>J. Neurosci.
<volume>25</volume>, <fpage>8048</fpage>–<lpage>8055</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1777-05.2005</pub-id><pub-id pub-id-type="pmid">16135762</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Vecchio</surname><given-names>R. A.</given-names></name><name><surname>Gold</surname><given-names>L. H.</given-names></name><name><surname>Novick</surname><given-names>S. J.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Hyde</surname><given-names>L. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Increased seizure threshold and severity in young transgenic CRND8 mice</article-title>. <source/>Neurosci. Lett.
<volume>367</volume>, <fpage>164</fpage>–<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2004.05.107</pub-id><pub-id pub-id-type="pmid">15331144</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolen</surname><given-names>G.</given-names></name><name><surname>Osterweil</surname><given-names>E.</given-names></name><name><surname>Rao</surname><given-names>B. S.</given-names></name><name><surname>Smith</surname><given-names>G. B.</given-names></name><name><surname>Auerbach</surname><given-names>B. D.</given-names></name><name><surname>Chattarji</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Correction of Fragile X Syndrome in Mice</article-title>. <source/>Neuron
<volume>56</volume>, <fpage>955</fpage>–<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.12.001</pub-id><pub-id pub-id-type="pmid">18093519</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erickson</surname><given-names>C. A.</given-names></name><name><surname>Ray</surname><given-names>B.</given-names></name><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Wink</surname><given-names>L. K.</given-names></name><name><surname>Bowers</surname><given-names>K.</given-names></name><name><surname>Schaefer</surname><given-names>T. L.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Impact of acamprosate on plasma amyloid-beta precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker</article-title>. <source/>J. Psychiatr. Res.
<volume>59</volume>, <fpage>220</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2014.07.011</pub-id><pub-id pub-id-type="pmid">25300441</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>S. T.</given-names></name><name><surname>Klein</surname><given-names>W. L.</given-names></name></person-group> (<year>2011</year>). <article-title>The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease</article-title>. <source/>Neurobiol. Learn. Mem.
<volume>96</volume>, <fpage>529</fpage>–<lpage>543</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2011.08.003</pub-id><pub-id pub-id-type="pmid">21914486</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatto</surname><given-names>C. L.</given-names></name><name><surname>Broadie</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models</article-title>. <source/>Front. Synaptic Neurosci.
<volume>2</volume>:<fpage>4</fpage>. <pub-id pub-id-type="doi">10.3389/fnsyn.2010.00004</pub-id><pub-id pub-id-type="pmid">21423490</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>J. R.</given-names></name><name><surname>Bartley</surname><given-names>A. F.</given-names></name><name><surname>Hays</surname><given-names>S. A.</given-names></name><name><surname>Huber</surname><given-names>K. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome</article-title>. <source/>J. Neurophysiol.
<volume>100</volume>, <fpage>2615</fpage>–<lpage>2626</lpage>. <pub-id pub-id-type="doi">10.1152/jn.90752.2008</pub-id><pub-id pub-id-type="pmid">18784272</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goncalves</surname><given-names>J. T.</given-names></name><name><surname>Anstey</surname><given-names>J. E.</given-names></name><name><surname>Golshani</surname><given-names>P.</given-names></name><name><surname>Portera-Cailliau</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Circuit level defects in the developing neocortex of Fragile X mice</article-title>. <source/>Nat. Neurosci.
<volume>16</volume>, <fpage>903</fpage>–<lpage>909</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3415</pub-id><pub-id pub-id-type="pmid">23727819</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>L. T.</given-names></name><name><surname>Strittmatter</surname><given-names>S. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Oligomers of amyloid beta prevent physiological activation of the cellular prion protein-metabotropic glutamate receptor 5 complex by glutamate in Alzheimer disease</article-title>. <source/>J. Biol. Chem.
<volume>291</volume>, <fpage>17112</fpage>–<lpage>17121</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.720664</pub-id><pub-id pub-id-type="pmid">27325698</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hays</surname><given-names>S. A.</given-names></name><name><surname>Huber</surname><given-names>K. M.</given-names></name><name><surname>Gibson</surname><given-names>J. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>14223</fpage>–<lpage>14234</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3157-11.2011</pub-id><pub-id pub-id-type="pmid">21976507</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Nomura</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Contractor</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>The developmental switch in GABA polarity is delayed in fragile X mice</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>446</fpage>–<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4447-13.2014</pub-id><pub-id pub-id-type="pmid">24403144</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeffer</surname><given-names>C. A.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><name><surname>Hagerman</surname><given-names>R. J.</given-names></name><name><surname>Mu</surname><given-names>Y.</given-names></name><name><surname>Nguyen</surname><given-names>D. V.</given-names></name><name><surname>Wong</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome</article-title>. <source/>Genes Brain Behav.
<volume>11</volume>, <fpage>332</fpage>–<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2012.00768.x</pub-id><pub-id pub-id-type="pmid">22268788</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>N. W.</given-names></name><name><surname>Nicoll</surname><given-names>A. J.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Mably</surname><given-names>A. J.</given-names></name><name><surname>O'Malley</surname><given-names>T.</given-names></name><name><surname>Purro</surname><given-names>S. A.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression <italic>in vivo</italic></article-title>. <source/>Nat. Commun.
<volume>5</volume>:<fpage>3374</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms4374</pub-id><pub-id pub-id-type="pmid">24594908</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>P.</given-names></name><name><surname>Warren</surname><given-names>S. T.</given-names></name></person-group> (<year>2000</year>). <article-title>Understanding the molecular basis of fragile X syndrome</article-title>. <source/>Hum. Mol. Genet.
<volume>9</volume>, <fpage>901</fpage>–<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/9.6.901</pub-id><pub-id pub-id-type="pmid">10767313</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamenetz</surname><given-names>F.</given-names></name><name><surname>Tomita</surname><given-names>T.</given-names></name><name><surname>Hsieh</surname><given-names>H.</given-names></name><name><surname>Seabrook</surname><given-names>G.</given-names></name><name><surname>Borchelt</surname><given-names>D.</given-names></name><name><surname>Iwatsubo</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>APP processing and synaptic function</article-title>. <source/>Neuron
<volume>37</volume>, <fpage>925</fpage>–<lpage>937</lpage>. <pub-id pub-id-type="doi">10.1016/S0896-6273(03)00124-7</pub-id><pub-id pub-id-type="pmid">12670422</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>D.</given-names></name><name><surname>Zeller</surname><given-names>M.</given-names></name><name><surname>Cole</surname><given-names>T.</given-names></name><name><surname>Buttini</surname><given-names>M.</given-names></name><name><surname>McConlogue</surname><given-names>L.</given-names></name><name><surname>Sinha</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease</article-title>. <source/>Neurobiol. Aging
<volume>29</volume>, <fpage>861</fpage>–<lpage>873</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.01.002</pub-id><pub-id pub-id-type="pmid">17331621</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalonde</surname><given-names>R.</given-names></name><name><surname>Dumont</surname><given-names>M.</given-names></name><name><surname>Staufenbiel</surname><given-names>M.</given-names></name><name><surname>Strazielle</surname><given-names>C.</given-names></name></person-group> (<year>2005</year>). <article-title>Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen</article-title>. <source/>Behav. Brain Res.
<volume>157</volume>, <fpage>91</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2004.06.020</pub-id><pub-id pub-id-type="pmid">15617775</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>B. T.</given-names></name><name><surname>Call</surname><given-names>L. M.</given-names></name><name><surname>Slunt</surname><given-names>H. H.</given-names></name><name><surname>Bardel</surname><given-names>K. A.</given-names></name><name><surname>Lawler</surname><given-names>A. M.</given-names></name><name><surname>Eckman</surname><given-names>C. B.</given-names></name><etal></etal></person-group>. (<year>1997</year>). <article-title>Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice</article-title>. <source/>Hum. Mol. Genet.
<volume>6</volume>, <fpage>1535</fpage>–<lpage>1541</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/6.9.1535</pub-id><pub-id pub-id-type="pmid">9285791</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>T.</given-names></name><name><surname>Hoeffer</surname><given-names>C. A.</given-names></name><name><surname>Capetillo-Zarate</surname><given-names>E.</given-names></name><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Wong</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>M. T.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease</article-title>. <source/>PLoS ONE
<volume>5</volume>:<fpage>e12845</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0012845</pub-id><pub-id pub-id-type="pmid">20862226</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlin</surname><given-names>L. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Differential roles for mGluR1 and mGluR5 in the persistent prolongation of epileptiform bursts</article-title>. <source/>J. Neurophysiol.
<volume>87</volume>, <fpage>621</fpage>–<lpage>625</lpage>. <pub-id pub-id-type="pmid">11784776</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlin</surname><given-names>L. R.</given-names></name><name><surname>Wong</surname><given-names>R. K.</given-names></name></person-group> (<year>1997</year>). <article-title>Role of group I metabotropic glutamate receptors in the patterning of epileptiform activities <italic>in vitro</italic></article-title>. <source/>J. Neurophysiol.
<volume>78</volume>, <fpage>539</fpage>–<lpage>544</lpage>. <pub-id pub-id-type="pmid">9242303</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalon</surname><given-names>A.</given-names></name><name><surname>Bruns</surname><given-names>A.</given-names></name><name><surname>Risterucci</surname><given-names>C.</given-names></name><name><surname>Honer</surname><given-names>M.</given-names></name><name><surname>Ballard</surname><given-names>T. M.</given-names></name><name><surname>Ozmen</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice</article-title>. <source/>Biol. Psychiatry
<volume>75</volume>, <fpage>189</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2013.05.038</pub-id><pub-id pub-id-type="pmid">23910948</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalon</surname><given-names>A.</given-names></name><name><surname>Sidorov</surname><given-names>M.</given-names></name><name><surname>Ballard</surname><given-names>T. M.</given-names></name><name><surname>Ozmen</surname><given-names>L.</given-names></name><name><surname>Spooren</surname><given-names>W.</given-names></name><name><surname>Wettstein</surname><given-names>J. G.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice</article-title>. <source/>Neuron
<volume>74</volume>, <fpage>49</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.03.009</pub-id><pub-id pub-id-type="pmid">22500629</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minkeviciene</surname><given-names>R.</given-names></name><name><surname>Rheims</surname><given-names>S.</given-names></name><name><surname>Dobszay</surname><given-names>M. B.</given-names></name><name><surname>Zilberter</surname><given-names>M.</given-names></name><name><surname>Hartikainen</surname><given-names>J.</given-names></name><name><surname>Fülöp</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>3453</fpage>–<lpage>3462</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5215-08.2009</pub-id><pub-id pub-id-type="pmid">19295151</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moechars</surname><given-names>D.</given-names></name><name><surname>Lorent</surname><given-names>K.</given-names></name><name><surname>De Strooper</surname><given-names>B.</given-names></name><name><surname>Dewachter</surname><given-names>I.</given-names></name><name><surname>Van Leuven</surname><given-names>F.</given-names></name></person-group> (<year>1996</year>). <article-title>Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice</article-title>. <source/>EMBO J.
<volume>15</volume>, <fpage>1265</fpage>–<lpage>1274</lpage>. <pub-id pub-id-type="pmid">8635459</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucke</surname><given-names>L.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name><name><surname>Yu</surname><given-names>G. Q.</given-names></name><name><surname>Mallory</surname><given-names>M.</given-names></name><name><surname>Rockenstein</surname><given-names>E. M.</given-names></name><name><surname>Tatsuno</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation</article-title>. <source/>J. Neurosci.
<volume>20</volume>, <fpage>4050</fpage>–<lpage>4058</lpage>. <pub-id pub-id-type="pmid">10818140</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>U.</given-names></name><name><surname>Nalavadi</surname><given-names>V.</given-names></name><name><surname>Nakamoto</surname><given-names>M.</given-names></name><name><surname>Pallas</surname><given-names>D. C.</given-names></name><name><surname>Ceman</surname><given-names>S.</given-names></name><name><surname>Bassell</surname><given-names>G. J.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A</article-title>. <source/>J. Neurosci.
<volume>27</volume>, <fpage>14349</fpage>–<lpage>14357</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2969-07.2007</pub-id><pub-id pub-id-type="pmid">18160642</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterweil</surname><given-names>E. K.</given-names></name><name><surname>Chuang</surname><given-names>S. C.</given-names></name><name><surname>Chubykin</surname><given-names>A. A.</given-names></name><name><surname>Sidorov</surname><given-names>M.</given-names></name><name><surname>Bianchi</surname><given-names>R.</given-names></name><name><surname>Wong</surname><given-names>R. K.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile x syndrome</article-title>. <source/>Neuron
<volume>77</volume>, <fpage>243</fpage>–<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.01.034</pub-id><pub-id pub-id-type="pmid">23352161</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterweil</surname><given-names>E. K.</given-names></name><name><surname>Krueger</surname><given-names>D. D.</given-names></name><name><surname>Reinhold</surname><given-names>K.</given-names></name><name><surname>Bear</surname><given-names>M. F.</given-names></name></person-group> (<year>2010</year>). <article-title>Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome</article-title>. <source/>J. Neurosci.
<volume>30</volume>, <fpage>15616</fpage>–<lpage>15627</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3888-10.2010</pub-id><pub-id pub-id-type="pmid">21084617</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palop</surname><given-names>J. J.</given-names></name><name><surname>Chin</surname><given-names>J.</given-names></name><name><surname>Roberson</surname><given-names>E. D.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Thwin</surname><given-names>M. T.</given-names></name><name><surname>Bien-Ly</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease</article-title>. <source/>Neuron
<volume>55</volume>, <fpage>697</fpage>–<lpage>711</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.07.025</pub-id><pub-id pub-id-type="pmid">17785178</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisiadou</surname><given-names>L.</given-names></name><name><surname>Bethani</surname><given-names>I.</given-names></name><name><surname>Michaki</surname><given-names>V.</given-names></name><name><surname>Krousti</surname><given-names>K.</given-names></name><name><surname>Rapti</surname><given-names>G.</given-names></name><name><surname>Efthimiopoulos</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Homer2 and Homer3 interact with amyloid precursor protein and inhibit Abeta production</article-title>. <source/>Neurobiol. Dis.
<volume>30</volume>, <fpage>353</fpage>–<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2008.02.004</pub-id><pub-id pub-id-type="pmid">18387811</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasciuto</surname><given-names>E.</given-names></name><name><surname>Ahmed</surname><given-names>T.</given-names></name><name><surname>Wahle</surname><given-names>T.</given-names></name><name><surname>Gardoni</surname><given-names>F.</given-names></name><name><surname>D'Andrea</surname><given-names>L.</given-names></name><name><surname>Pacini</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Dysregulated ADAM10-mediated processing of APP during a critical time window leads to synaptic deficits in fragile X syndrome</article-title>. <source/>Neuron
<volume>87</volume>, <fpage>382</fpage>–<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.06.032</pub-id><pub-id pub-id-type="pmid">26182420</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prox</surname><given-names>J.</given-names></name><name><surname>Bernreuther</surname><given-names>C.</given-names></name><name><surname>Altmeppen</surname><given-names>H.</given-names></name><name><surname>Grendel</surname><given-names>J.</given-names></name><name><surname>Glatzel</surname><given-names>M.</given-names></name><name><surname>D'Hooge</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions</article-title>. <source/>J. Neurosci.
<volume>33</volume>, <fpage>12915</fpage>–<lpage>12928</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.5910-12.2013</pub-id><pub-id pub-id-type="pmid">23926248</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>B.</given-names></name><name><surname>Sokol</surname><given-names>D. K.</given-names></name><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Lahiri</surname><given-names>D. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Finding novel distinctions between the sAPPalpha-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue</article-title>. <source/>Sci. Rep.
<volume>6</volume>:<fpage>26052</fpage>. <pub-id pub-id-type="doi">10.1038/srep26052</pub-id><pub-id pub-id-type="pmid">27212113</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renner</surname><given-names>M.</given-names></name><name><surname>Lacor</surname><given-names>P. N.</given-names></name><name><surname>Velasco</surname><given-names>P. T.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Contractor</surname><given-names>A.</given-names></name><name><surname>Klein</surname><given-names>W. L.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5</article-title>. <source/>Neuron
<volume>66</volume>, <fpage>739</fpage>–<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.04.029</pub-id><pub-id pub-id-type="pmid">20547131</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronesi</surname><given-names>J. A.</given-names></name><name><surname>Collins</surname><given-names>K. A.</given-names></name><name><surname>Hays</surname><given-names>S. A.</given-names></name><name><surname>Tsai</surname><given-names>N.-P.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Birnbaum</surname><given-names>S. G.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome</article-title>. <source/>Nat. Neurosci. <volume>15</volume>, <fpage>431</fpage>–<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3033</pub-id><pub-id pub-id-type="pmid">22267161</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roselli</surname><given-names>F.</given-names></name><name><surname>Hutzler</surname><given-names>P.</given-names></name><name><surname>Wegerich</surname><given-names>Y.</given-names></name><name><surname>Livrea</surname><given-names>P.</given-names></name><name><surname>Almeida</surname><given-names>O. F.</given-names></name></person-group> (<year>2009</year>). <article-title>Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways</article-title>. <source/>PLoS ONE
<volume>4</volume>:<fpage>e6011</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0006011</pub-id><pub-id pub-id-type="pmid">19547699</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>P. E.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Verret</surname><given-names>L.</given-names></name><name><surname>Vossel</surname><given-names>K. A.</given-names></name><name><surname>Orr</surname><given-names>A. G.</given-names></name><name><surname>Cirrito</surname><given-names>J. R.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>109</volume>, <fpage>E2895</fpage>–<lpage>E2903</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1121081109</pub-id><pub-id pub-id-type="pmid">22869752</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokol</surname><given-names>D. K.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Farlow</surname><given-names>M. R.</given-names></name><name><surname>Dunn</surname><given-names>D. W.</given-names></name><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Zimmer</surname><given-names>J. A.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression</article-title>. <source/>J. Child Neurol.
<volume>21</volume>, <fpage>444</fpage>–<lpage>449</lpage>. <pub-id pub-id-type="pmid">16948926</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbach</surname><given-names>J. P.</given-names></name><name><surname>Müller</surname><given-names>U.</given-names></name><name><surname>Leist</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Z. W.</given-names></name><name><surname>Nicotera</surname><given-names>P.</given-names></name><name><surname>Aguzzi</surname><given-names>A.</given-names></name></person-group> (<year>1998</year>). <article-title>Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice</article-title>. <source/>Cell Death Differ.
<volume>5</volume>, <fpage>858</fpage>–<lpage>866</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cdd.4400391</pub-id><pub-id pub-id-type="pmid">10203685</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q. Q.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Szabo</surname><given-names>G.</given-names></name><name><surname>Erdelyi</surname><given-names>F.</given-names></name></person-group> (<year>2009</year>). <article-title>Differential metabotropic glutamate receptor expression and modulation in two neocortical inhibitory networks</article-title>. <source/>J. Neurophysiol.
<volume>101</volume>, <fpage>2679</fpage>–<lpage>2692</lpage>. <pub-id pub-id-type="doi">10.1152/jn.90566.2008</pub-id><pub-id pub-id-type="pmid">19244358</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tranfaglia</surname><given-names>M. R.</given-names></name></person-group> (<year>2011</year>). <article-title>The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome</article-title>. <source/>Dev. Neurosci.
<volume>33</volume>, <fpage>337</fpage>–<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1159/000329421</pub-id><pub-id pub-id-type="pmid">21893938</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Um</surname><given-names>J. W.</given-names></name><name><surname>Kaufman</surname><given-names>A. C.</given-names></name><name><surname>Kostylev</surname><given-names>M.</given-names></name><name><surname>Heiss</surname><given-names>J. K.</given-names></name><name><surname>Stagi</surname><given-names>M.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Abeta oligomer bound to cellular prion protein</article-title>. <source/>Neuron
<volume>79</volume>, <fpage>887</fpage>–<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.06.036</pub-id><pub-id pub-id-type="pmid">24012003</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name></person-group> (<year>2013</year>). <article-title>What's hAPPening at synapses? The role of amyloid β-protein precursor and beta-amyloid in neurological disorders</article-title>. <source/>Mol. Psychiatry
<volume>18</volume>, <fpage>425</fpage>–<lpage>434</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2012.122</pub-id><pub-id pub-id-type="pmid">22925831</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Berry-Kravis</surname><given-names>E. M.</given-names></name><name><surname>Ikonomidou</surname><given-names>C.</given-names></name><name><surname>Yin</surname><given-names>J. C.</given-names></name><name><surname>Puglielli</surname><given-names>L.</given-names></name></person-group> (<year>2013b</year>). <article-title>Developing BACE-1 inhibitors for FXS</article-title>. <source/>Front. Cell. Neurosci.
<volume>7</volume>:<fpage>77</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2013.00077</pub-id><pub-id pub-id-type="pmid">23754978</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Malter</surname><given-names>J. S.</given-names></name></person-group> (<year>2007</year>). <article-title>FMRP mediates mGluR5-dependent translation of amyloid precursor protein</article-title>. <source/>PLoS Biol.
<volume>5</volume>:<fpage>e52</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.0050052</pub-id><pub-id pub-id-type="pmid">17298186</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Malter</surname><given-names>J. S.</given-names></name></person-group> (<year>2012</year>). <article-title>The regulation of AβPP expression by RNA-binding proteins</article-title>. <source/>Ageing Res. Rev. <volume>11</volume>, <fpage>450</fpage>–<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2012.03.005</pub-id><pub-id pub-id-type="pmid">22504584</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Sokol</surname><given-names>D. K.</given-names></name><name><surname>Maloney</surname><given-names>B.</given-names></name><name><surname>Lahiri</surname><given-names>D. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome an autism</article-title>. <source/>Mol. Psychiatry
<volume>21</volume>, <fpage>1333</fpage>–<lpage>1341</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.134</pub-id><pub-id pub-id-type="pmid">27573877</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Westmark</surname><given-names>P. R.</given-names></name><name><surname>Beard</surname><given-names>A. M.</given-names></name><name><surname>Hildebrandt</surname><given-names>S. M.</given-names></name><name><surname>Malter</surname><given-names>J. S.</given-names></name></person-group> (<year>2008</year>). <article-title>Seizure susceptibility and mortality in mice that over-express amyloid precursor protein</article-title>. <source/>Int. J. Clin. Exp. Pathol.
<volume>1</volume>, <fpage>157</fpage>–<lpage>168</lpage>. <pub-id pub-id-type="pmid">18784809</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Westmark</surname><given-names>P. R.</given-names></name><name><surname>Malter</surname><given-names>J. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures</article-title>. <source/>J. Alzheimers. Dis.
<volume>20</volume>, <fpage>1009</fpage>–<lpage>1013</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2010-100087</pub-id><pub-id pub-id-type="pmid">20413855</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Westmark</surname><given-names>P. R.</given-names></name><name><surname>Malter</surname><given-names>J. S.</given-names></name></person-group> (<year>2013a</year>). <article-title>Soy-based diet exacerbates seizures in mouse models of neurological disease</article-title>. <source/>J. Alzheimers. Dis.
<volume>33</volume>, <fpage>797</fpage>–<lpage>805</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2012-121426</pub-id><pub-id pub-id-type="pmid">23034522</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Westmark</surname><given-names>P. R.</given-names></name><name><surname>O'Riordan</surname><given-names>K. J.</given-names></name><name><surname>Ray</surname><given-names>B. C.</given-names></name><name><surname>Hervey</surname><given-names>C. M.</given-names></name><name><surname>Salamat</surname><given-names>M. S.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Reversal of Fragile X Phenotypes by Manipulation of AbetaPP/Abeta Levels in Fmr1 Mice</article-title>. <source/>PLoS ONE
<volume>6</volume>:<fpage>e26549</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0026549</pub-id><pub-id pub-id-type="pmid">22046307</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>R. K.</given-names></name><name><surname>Chuang</surname><given-names>S. C.</given-names></name><name><surname>Bianchi</surname><given-names>R.</given-names></name></person-group> (<year>2004</year>). <article-title>Plasticity mechanisms underlying mGluR-induced epileptogenesis</article-title>. <source/>Adv. Exp. Med. Biol.
<volume>548</volume>, <fpage>69</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4757-6376-8_5</pub-id><pub-id pub-id-type="pmid">15250586</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>K. F.</given-names></name><name><surname>Pasternak</surname><given-names>S. H.</given-names></name><name><surname>Rylett</surname><given-names>R. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Oligomeric aggregates of amyloid beta peptide 1-42 activate ERK/MAPK in SH-SY5Y cells via the alpha7 nicotinic receptor</article-title>. <source/>Neurochem. Int.
<volume>55</volume>, <fpage>796</fpage>–<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2009.08.002</pub-id><pub-id pub-id-type="pmid">19666073</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Bianchi</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Wong</surname><given-names>R. K.</given-names></name></person-group> (<year>2004</year>). <article-title>Extracellular signal-regulated kinase 1/2 is required for the induction of group I metabotropic glutamate receptor-mediated epileptiform discharges</article-title>. <source/>J. Neurosci.
<volume>24</volume>, <fpage>76</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4515-03.2004</pub-id><pub-id pub-id-type="pmid">14715940</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Chuang</surname><given-names>S. C.</given-names></name><name><surname>Bianchi</surname><given-names>R.</given-names></name><name><surname>Wong</surname><given-names>R. K.</given-names></name></person-group> (<year>2011</year>). <article-title>Dual regulation of fragile X mental retardation protein by group I metabotropic glutamate receptors controls translation-dependent epileptogenesis in the hippocampus</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>725</fpage>–<lpage>734</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2915-10.2011</pub-id><pub-id pub-id-type="pmid">21228181</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J.</given-names></name><name><surname>Chuang</surname><given-names>S. C.</given-names></name><name><surname>Bianchi</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Fenton</surname><given-names>A. A.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>BC1 regulation of metabotropic glutamate receptor-mediated neuronal excitability</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>9977</fpage>–<lpage>9986</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3893-08.2009</pub-id><pub-id pub-id-type="pmid">19675232</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziyatdinova</surname><given-names>S.</given-names></name><name><surname>Gurevicius</surname><given-names>K.</given-names></name><name><surname>Kutchiashvili</surname><given-names>N.</given-names></name><name><surname>Bolkvadze</surname><given-names>T.</given-names></name><name><surname>Nissinen</surname><given-names>J.</given-names></name><name><surname>Tanila</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels</article-title>. <source/>Epilepsy Res.
<volume>94</volume>, <fpage>75</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2011.01.003</pub-id><pub-id pub-id-type="pmid">21300523</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>